TFII.TO -1.7C -0.18MU -19.63CRWD 5.69PANW 4.39SNOW 16.89V 3.35MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
WEAK BUY

Pfizer Inc(PFE)

Nov 22, 2006
Pharmaceutical sector is trading at very low valuations. Prefers Wyeth (WYE-N), which has a better growth profile, better portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$27.10

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 07, 2006
His top choice in large pharmas is Eli Lilly (LLY-N). One of the major concerns that pharmacy companies have is patent expiration and generics coming in. This company is not well positioned to fend off generics.
Photo of Ian NakamotoIan NakamotoUnlock Rating
$27.29

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 31, 2006
(A Top Pick July 11/06. Up 12.8%.) 3.6 % dividend. Still more upside. But pipeline. Money continues to flow into the multinationals, which will benefit this company.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.65

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 23, 2006
3.4% dividend. The stock has been steadily rising over the last four months. Should be a core holding.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$27.73

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 19, 2006
This group has been forgotten over the last 5 years as it wildly under-performed the market. They all went to virtually zero growth rate and now there is a pick up. There is cost cutting and they are under owned. Likes this space. This would not be his number one choice but it is okay.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.68

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 17, 2006
Reached his model price and he sold his holdings.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$27.72

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2006
Pipeline has been a little hurt because of competition, but the valuation is as cheap as it has been in 20 years.
Photo of John ZechnerJohn ZechnerUnlock Rating
$27.66

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 10, 2006
His favourite large drug stock. Has been beaten up pretty badly. Has a great product pipeline, even with patents coming off. Swimming in cash. Doing a share buyback and have increased their dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$27.56

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 04, 2006
Very cheap. Pays a nice yield. There were some issues with management and there has been a change. The pharmaceutical industry as a whole is undervalued.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 27, 2006
The stock has increased since he picked it. They have raised their dividends. It has a high yield. He continues to own.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$28.41

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2006
Good value for a bounce. Expects another 15/20% upside. Treating it as a Trade, not for the long term.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$28.16

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2006
Likes it and still buying for new clients. Have a pipeline of new drugs and using their cash to develop new drugs. Have sold their consumer products division. Have increased their dividends and doing buybacks.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.98

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 17, 2006
His 2 favourite pharmaceuticals are Glaxosmithkline (GSK-N) and Johnson & Johnson (JNJ-N). This company is having so much trouble right now that they are on their 3rd CEO in the last 5/6 years. Have patent problems and sales are declining. Outstanding lawsuits.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$27.00

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 09, 2006
Big issue is 20% of revenue and a larger % of profits comes from one drug, Lipitor, which will get generic competition. Sold their consumer business and have other products in the pipeline and they are buying back mountains of its own stock. Dividend share is significant.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$26.15

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 03, 2006
A defensive position. Very cheap. Lots of value and seems to have momentum.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$25.21

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 601 to 615 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.68$146.01
SLB -1.22$48.37
SHEL -0.8$91.18
AAPL -2.76$306.15
AMZN 12.275$283.855

Today's Top Picks

TFII.TO -1.7$13.38
C -0.18$132.27
MU -19.63$803.4
CRWD 5.69$196.55
PANW 4.39$336.22

Popular Articles

Latest Sell Signals

AAPL -2.76$306.15
AAPL -2.76$306.15
AAPL -2.76$306.15
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like